Vaxart (NASDAQ:VXRT) Posts Quarterly Earnings Results

Vaxart (NASDAQ:VXRT) issued its earnings results on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05, Zacks reports. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. The company had revenue of $15.19 million during the quarter, compared to analysts’ expectations of $15.68 million.

Vaxart Stock Performance

Shares of NASDAQ:VXRT opened at $0.52 on Friday. The company has a market capitalization of $117.40 million, a P/E ratio of -1.26 and a beta of 1.69. Vaxart has a 52-week low of $0.45 and a 52-week high of $1.41. The company has a 50-day simple moving average of $0.65 and a 200 day simple moving average of $0.71.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.